Recent developments include leadership changes, patent filings, clinical progress towards first-in-human trials, and business development appointments.

• Akari Therapeutics announced new CEO and director changes in March 2026, appointing Abizer Gaslightwala as President and CEO [N1].
• The company filed a key patent and unveiled a second ADC program, AKTX-102 targeting CEACAM5 expressing solid tumors, in January 2026 [N2].
• Ladenburg Thalmann initiated coverage of Akari Therapeutics with a buy recommendation in early January 2026 [N3].
• Akari advanced towards a first-in-human trial with its novel ADC payload, targeting a Phase 1 trial start in late 2026 or early 2027 [N4].
• The company reported promising preclinical data advancing PH1 spliceosome modulator research for cancer treatment in July 2025 [N6].
• Akari secured a patent for its PH1 cancer therapy amid rising cancer rates in India in June 2025 [N7].
• The company appointed a new head of business development for oncology and advanced its novel antibody drug conjugates in May 2025 [N8].

Akari Therapeutics' novel PH1 payload demonstrates promising preclinical efficacy with a unique dual mechanism of action combining cytotoxicity and immune activation. The lead candidate AKTX-101 has shown superior activity compared to existing ADCs and potential synergy with checkpoint inhibitors, which could address significant unmet needs in multiple solid tumor types. The company’s expanding pipeline, including AKTX-102 targeting CEACAM5, and its broad patent portfolio support potential future growth. Strategic partnerships and recent leadership appointments may enhance development and commercialization capabilities.

Akari Therapeutics faces significant risks including the early-stage nature of its pipeline with no products yet in clinical trials or approved for commercial use. The company has a history of operating losses, limited liquidity, and depends on raising additional capital to fund ongoing research and development. The ADC field is competitive with established therapies and other companies developing Trop-2 and CEACAM5 targeting agents. Regulatory, clinical, and market acceptance challenges may impede progress. Nasdaq listing compliance issues and potential dilution from future financings also pose risks to shareholders.

Akari Therapeutics' moat is centered on its proprietary PH1 payload platform, which offers a novel mechanism of action by targeting RNA splicing and inducing both direct cytotoxicity and immune activation. This dual mode of action differentiates its ADC candidates from existing therapies that primarily use microtubule inhibitors or DNA-damaging agents. The company has secured patents covering its payload and ADC constructs in multiple key markets, providing intellectual property protection. Additionally, its early-stage pipeline targeting multiple cancer antigens and the potential to overcome multidrug resistance mechanisms contribute to its competitive positioning. However, the moat is contingent on successful clinical development and regulatory approval, which remain uncertain.

• Clinical and Regulatory Risk: The company has not initiated clinical development of its product candidates and faces uncertainties in obtaining regulatory approvals necessary for commercialization.
• Financial Risk: Akari Therapeutics has a history of operating losses, limited cash resources, and will require substantial additional capital to continue operations and fund development activities.
• Competitive Risk: The oncology ADC market is competitive with existing approved therapies and multiple clinical-stage programs targeting similar antigens, which may limit market acceptance.
• Operational Risk: The company currently has limited sales, marketing, and distribution capabilities and relies on third-party manufacturers, which may affect commercialization readiness.
• Market Listing Risk: The company has received Nasdaq notices regarding minimum bid price non-compliance, posing a risk of delisting if compliance is not regained.

• Akari Therapeutics Plc is an oncology company developing next-generation antibody-drug conjugates (ADCs) with novel proprietary payloads targeting cancer cells by disrupting RNA splicing via modulation of the spliceosome.
• The lead payload, PH1, has a dual mode of action: cytotoxicity causing cancer cell death and generation of neoantigens that activate innate and adaptive immune systems, demonstrated in preclinical models.
• The lead product candidate, AKTX-101, targets the Trop-2 receptor on cancer cells and is engineered with a proprietary linker to deliver PH1 payload with minimal off-target effects.
• AKTX-101 has shown significant activity and prolonged survival in preclinical animal models compared to ADCs with traditional payloads, and potential synergy with checkpoint inhibitors.
• The company is advancing AKTX-101 towards a first-in-human Phase 1 trial targeted for late 2026 or early 2027, with ongoing IND enabling studies and GMP manufacturing initiated with WuXi Biologics.
• A second ADC program, AKTX-102, targets CEACAM5, relevant in pancreatic, colon, stomach, esophageal, and lung cancers, and is in discovery/preclinical stage with plans to advance.
• The company’s ADC platform allows generation of multiple ADC candidates focused on different cancer antigen targets using the PH1 payload.
• PH1 payload is designed to evade multidrug resistance mechanisms common in cancer cells, maintaining cytotoxic potency where other payloads lose effectiveness.
• Preclinical studies show PH1 induces a strong immune response including neoepitope formation, immune cell activation, and immunological memory in animal models.
• The company has filed and maintains patents covering the PH1 payload and ADC platform in multiple jurisdictions including the US, China, India, and Europe.
• Akari Therapeutics has limited sales, marketing, and distribution capabilities currently, with plans to build or outsource these functions if product candidates are approved.
• The company relies on third-party contract manufacturers for development and GMP production of clinical materials.
• Financial snapshot as of December 31, 2025: cash and equivalents $0, current assets $5.46 million, current liabilities $12.35 million, current ratio 0.44, net loss $17.3 million, EPS basic and diluted $0.
• The company has a history of operating losses and has not generated revenue from product sales to date, with accumulated deficit of $264.5 million as of December 31, 2025.
• Recent leadership changes include appointment of Abizer Gaslightwala as President and CEO and new head of business development for oncology.
• Recent financing activities include a registered direct offering and private placement raising approximately $5 million in gross proceeds, plus liability reduction totaling about $9 million.
• The company faces risks including the need for substantial additional capital, regulatory approval uncertainties, competition from existing and emerging oncology therapies, and Nasdaq listing compliance risks.